Literature DB >> 28655517

Safety assessment of green tea based beverages and dried green tea extracts as nutritional supplements.

Wolfgang Dekant1, Kenkichi Fujii2, Eiichiro Shibata3, Osamu Morita2, Akira Shimotoyodome3.   

Abstract

The safety of green tea infusions and green tea extract (GTE)-based products is reviewed regarding catechins. Epigallocatechin 3-gallate (EGCG), the major catechin present in green tea, is suspected of being responsible for liver toxicity reported in humans consuming food supplements. Intake of EGCG with green tea infusions and GTE-based beverages is up to about 450mg EGCG/person/day in Europe and higher in Asia. Consumption of green tea is not associated with liver damage in humans, and green tea infusion and GTE-based beverages are considered safe in the range of historical uses. In animal studies, EGCG's potency for liver effects is highly dependent on conditions of administration. Use of NOAELs from bolus administration to derive a tolerable upper intake level applying the margin of safety concept results in acceptable EGCG-doses lower than those from one cup of green tea. NOAELs from toxicity studies applying EGCG with diet/split of the daily dose are a better point of departure for risk characterization. In clinical intervention studies, liver effects were not observed after intakes below 600mg EGCG/person/day. Thus, a tolerable upper intake level of 300mg EGCG/person/day is proposed for food supplements; this gives a twofold safety margin to clinical studies that did not report liver effects and a margin of safety of 100 to the NOAELs in animal studies with dietary administration of green tea catechins.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Catechins; Food supplements; Green tea; Safety assessment

Mesh:

Substances:

Year:  2017        PMID: 28655517     DOI: 10.1016/j.toxlet.2017.06.008

Source DB:  PubMed          Journal:  Toxicol Lett        ISSN: 0378-4274            Impact factor:   4.372


  14 in total

1.  Epigallocatechin gallate in multiple system atrophy (PROMESA).

Authors:  Kurt A Jellinger
Journal:  Ann Transl Med       Date:  2019-12

2.  Usage of and attitudes about green tea extract and Epigallocathechin-3-gallate (EGCG) as a therapy in individuals with Down syndrome.

Authors:  Rachel Long; Montana L Drawbaugh; Charlene M Davis; Charles R Goodlett; Jane R Williams; Randall J Roper
Journal:  Complement Ther Med       Date:  2019-07-02       Impact factor: 2.446

3.  Isolation, characterization and biological activities of betulin from Acacia nilotica bark.

Authors:  Prabhjit Kaur; Saroj Arora; Rajbir Singh
Journal:  Sci Rep       Date:  2022-06-07       Impact factor: 4.996

Review 4.  Dietary Supplements for Weight Management: A Narrative Review of Safety and Metabolic Health Benefits.

Authors:  Eunice Mah; Oliver Chen; DeAnn J Liska; Jeffrey B Blumberg
Journal:  Nutrients       Date:  2022-04-24       Impact factor: 6.706

5.  Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult Down syndrome mice.

Authors:  Charles R Goodlett; Megan Stringer; Jonathan LaCombe; Roshni Patel; Joseph M Wallace; Randall J Roper
Journal:  Sci Rep       Date:  2020-06-26       Impact factor: 4.379

Review 6.  Polyphenols with Anti-Amyloid β Aggregation Show Potential Risk of Toxicity Via Pro-Oxidant Properties.

Authors:  Hatasu Kobayashi; Mariko Murata; Shosuke Kawanishi; Shinji Oikawa
Journal:  Int J Mol Sci       Date:  2020-05-18       Impact factor: 5.923

7.  Green Tea Catechin Dramatically Promotes RNAi Mediated by Low-Molecular-Weight Polymers.

Authors:  Wanwan Shen; Qingwei Wang; Yang Shen; Xiao Gao; Lei Li; Yang Yan; Hui Wang; Yiyun Cheng
Journal:  ACS Cent Sci       Date:  2018-09-19       Impact factor: 14.553

Review 8.  United States Pharmacopeia (USP) comprehensive review of the hepatotoxicity of green tea extracts.

Authors:  Hellen A Oketch-Rabah; Amy L Roe; Cynthia V Rider; Herbert L Bonkovsky; Gabriel I Giancaspro; Victor Navarro; Mary F Paine; Joseph M Betz; Robin J Marles; Steven Casper; Bill Gurley; Scott A Jordan; Kan He; Mahendra P Kapoor; Theertham P Rao; Averell H Sherker; Robert J Fontana; Simona Rossi; Raj Vuppalanchi; Leonard B Seeff; Andrew Stolz; Jawad Ahmad; Christopher Koh; Jose Serrano; Tieraona Low Dog; Richard Ko
Journal:  Toxicol Rep       Date:  2020-02-15

Review 9.  Health Functions and Related Molecular Mechanisms of Tea Components: An Update Review.

Authors:  Guo-Yi Tang; Xiao Meng; Ren-You Gan; Cai-Ning Zhao; Qing Liu; Yi-Bin Feng; Sha Li; Xin-Lin Wei; Atanas G Atanasov; Harold Corke; Hua-Bin Li
Journal:  Int J Mol Sci       Date:  2019-12-08       Impact factor: 5.923

10.  The recent failure of the PROMESA clinical trial for multiple system atrophy raises the question-are polyphenols a viable therapeutic option against proteinopathies?

Authors:  Gal Bitan
Journal:  Ann Transl Med       Date:  2020-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.